Anthera Pharmaceuticals Inc (ANTH)
0.00
USD |
OTCM |
Apr 23, 16:00
Anthera Pharmaceuticals Enterprise Value
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 23, 2024 | -8.086M |
April 22, 2024 | -8.086M |
April 19, 2024 | -8.086M |
April 18, 2024 | -8.086M |
April 17, 2024 | -8.086M |
April 16, 2024 | -8.086M |
April 15, 2024 | -8.086M |
April 12, 2024 | -8.086M |
April 11, 2024 | -8.086M |
April 10, 2024 | -8.086M |
April 09, 2024 | -8.086M |
April 08, 2024 | -8.086M |
April 05, 2024 | -8.086M |
April 04, 2024 | -8.086M |
April 03, 2024 | -8.086M |
April 02, 2024 | -8.086M |
April 01, 2024 | -8.086M |
March 28, 2024 | -8.086M |
March 27, 2024 | -8.086M |
March 26, 2024 | -8.086M |
March 25, 2024 | -8.086M |
March 22, 2024 | -8.086M |
March 21, 2024 | -8.086M |
March 20, 2024 | -8.086M |
March 19, 2024 | -8.086M |
Date | Value |
---|---|
March 18, 2024 | -8.086M |
March 15, 2024 | -8.086M |
March 14, 2024 | -8.086M |
March 13, 2024 | -8.086M |
March 12, 2024 | -8.086M |
March 11, 2024 | -8.086M |
March 08, 2024 | -8.086M |
March 07, 2024 | -8.086M |
March 06, 2024 | -8.086M |
March 05, 2024 | -8.086M |
March 04, 2024 | -8.086M |
March 01, 2024 | -8.086M |
February 29, 2024 | -8.086M |
February 28, 2024 | -8.086M |
February 27, 2024 | -8.086M |
February 26, 2024 | -8.086M |
February 23, 2024 | -8.086M |
February 22, 2024 | -8.086M |
February 21, 2024 | -8.086M |
February 20, 2024 | -8.086M |
February 16, 2024 | -8.086M |
February 15, 2024 | -8.086M |
February 14, 2024 | -8.086M |
February 13, 2024 | -8.086M |
February 12, 2024 | -8.086M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-8.086M
Minimum
Oct 27 2021
-3.636M
Maximum
Feb 23 2021
-7.512M
Average
-8.065M
Median
Sep 27 2021
Enterprise Value Benchmarks
NovaBay Pharmaceuticals Inc | 2.275M |
Palatin Technologies Inc | 18.75M |
iBio Inc | 16.49M |
Theriva Biologics Inc | -13.75M |
Oragenics Inc | 3.306M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -7.724M |
Total Expenses (Quarterly) | 10.97M |
EPS Diluted (Quarterly) | -0.42 |